TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact
English
简体 English 繁体

Latest News

Press Release
2024-04-10
Transcenta Presents Osemitamab (TST001) and TST003 Study Results at AACR 2024
2024-04-09
Transcenta Announces Collaboration with Agilent to Develop a Claudin 18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
2023-12-13
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
More More
Events
2024-04-26
Transcenta to Present I/IIa Study Results of First-line Osemitamab (TST001) plus Nivolumab and CAPOX for Advanced G/GEJ Cancer at ASCO 2024
2024-03-26
Transcenta to Present Osemitamab (TST001) and TST003 Study Results at AACR 2024
More More


Innovation

Discovery

Employing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate therapeutic candidate leads with differentiated biological profile and enhanced druggability attributes.

Translational Research

Our translational research generates PK, PD, Tox and immunogenicity data through validated quantitative platforms, and enables us to model clinical responses to our investigational agents for better understanding of PK/PD/Safety profiles, which guides design and conduct of clinical studies.

Process Development

We can leverage both classical fed-batch and perfusion-based continuous bioprocessing technologies to enable fast-to-IND and fast-to-market process development.

Clinical Development

Based in Beijing, Shanghai, Guangzhou and Princeton, US, our teams at global clinical development centers and regulatory teams have extensive knowledge and experience in designing and executing clinical trials at all stages.

Manufacturing

Equipped with a flexible modular manufacturing facility and advanced next-generation perfusion bioprocessing platform, we are able to significantly accelerate process development and reduce the cost of manufacturing.

Partnering

Benefited from the global network and industry resources of our prominent shareholders with deep biotech expertise, we have forged multiple forms of important strategic cooperation with leading domestic and international pharmaceutical companies and equipment suppliers.

2012
Company Established
139
Issued & Pending Patents
13
Pipeline
2021
Listed in HKEX
6
Global Footprints